12:00 AM
 | 
Mar 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cholestagel: Phase III

Preliminary data from a 100-patient European Phase III trial showed that a 3.8 g once daily dose of Cholestagel had similar efficacy to two 1.9 g doses in the study's primary...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >